glp-1 diabetes GLP-1a: Going beyond Traditional Use

With imposing 100% tariffs on the import of pharmaceutical products due to start on 1 October (and whilst there has yet to be an Executive Order or Presidential Proclamation setting out the specific details), larger #pharma players such as Pfizer have already announced a reduction in #drugprices for US consumers and commitment to invest additional resources in the US to avoid additional tariffs

These inflammatory mediators further damage neurons and disrupt the BBB, allowing peripheral immune cells to infiltrate the CNS ( The interaction between excitotoxicity and neuroinflammation is critical for the development of long-term neurodegeneration

These conversations usually include reviewing differences between FDA-approved medications and compounded alternatives, understanding required monitoring, and confirming follow-up expectations

A story about GLP-1 agonists and their use in treating obesity and type II diabetes mellitus